IGF2BP2 has been implicated in suppressing anti-tumor immune responses, enhancing the function of immunosuppressive cells, adapting to hypoxic conditions, and driving cancer metabolism, angiogenesis, drug resistance, metastasis, and cell cycle progression. This evidence concerns the gene IGF2BP2 and neoplasm.